Oxybutynin and Infusion site pain - a phase IV clinical study of FDA data

Summary:

Infusion site pain is reported as a side effect among people who take Oxybutynin (oxybutynin), especially for people who are female, 60+ old, also take Proair Hfa, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Infusion site pain when taking Oxybutynin. It is created by eHealthMe based on reports of 22,833 people who have side effects when taking Oxybutynin from the FDA, and is updated regularly.

What is Oxybutynin?

Oxybutynin has active ingredients of oxybutynin. It is often used in urge incontinence. eHealthMe is studying from 23,143 Oxybutynin users. Check the latest studies of Oxybutynin.

What is Infusion site pain?

Infusion site pain is found to be associated with 750 drugs and 466 conditions by eHealthMe. Check the latest studies of Infusion site pain.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

22,833 people reported to have side effects when taking Oxybutynin.
Among them, 30 people (0.13%) have Infusion site pain.

Could Oxybutynin cause Infusion site pain?

Among these 30 people:

What is the gender of people who have Infusion site pain when taking Oxybutynin? *

female: 73.33 %
male: 26.67 %

What is the age of people who have Infusion site pain when taking Oxybutynin? *

What are other drugs people take besides Oxybutynin? *

What are other side effects people have besides Infusion site pain? *

Headache (pain in head): 9 people, 30.00%
Infusion Site Pruritus (severe itching at infusion site): 9 people, 30.00%
Sinusitis (inflammation of sinus): 8 people, 26.67%
Infusion Site Erythema (reddening of the skin at infusion site): 7 people, 23.33%
Infusion Site Swelling: 6 people, 20.00%
Feeling Abnormal: 6 people, 20.00%
Itching: 5 people, 16.67%
Pain: 5 people, 16.67%
White Blood Cell Count Decreased: 4 people, 13.33%
Neuropathy Peripheral (surface nerve damage): 4 people, 13.33%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 21 people, 70.00%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 3 people, 10.00%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 3.33%
Asthma: 1 person, 3.33%
Bedwetting: 1 person, 3.33%
Chest Pain: 1 person, 3.33%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 3.33%
High Blood Pressure: 1 person, 3.33%
Hypersensitivity: 1 person, 3.33%
Raynaud's Phenomenon (discoloration of the fingers, toes, and occasionally other areas): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Oxybutynin and have Infusion site pain?

- Check whether Infusion site pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oxybutynin:

Oxybutynin (23,143 reports)

Browse all side effects of Oxybutynin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site pain:

Infusion site pain (750 drugs)

Browse all the conditions that are associated with Infusion site pain:

Infusion site pain (466 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on oxybutynin (the active ingredients of Oxybutynin) and Oxybutynin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.